European journal of breast health最新文献

{"title":"Clinical Outcomes in Initial Hirudotherapy versus Standard Treatment in Idiopathic Granulomatous Mastitis: A Comparative Cohort Study.","authors":"Merve Tokoçin, Kayra Cangöz, Muhammed Bahadır Avcı, Mehmet Ölçüm, Adnan Gündoğdu, Ruziye Canan Aral Orhan, Hüseyin Kadıoğlu","doi":"10.4274/ejbh.galenos.2026.2026-3-7","DOIUrl":"10.4274/ejbh.galenos.2026.2026-3-7","url":null,"abstract":"<p><strong>Objective: </strong>Idiopathic granulomatous mastitis (IGM) is a chronic inflammatory disease characterized by a high risk of recurrence and fistula formation. Spontaneous remission has been reported in up to 50% of cases, particularly in mild forms, within 6-24 months without intervention, but inadequate management may allow disease progression. The aim of this study was to compare the clinical outcomes of patients who initially preferred hirudotherapy (leech therapy) with those managed with evidence-based stepwise conventional care.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed histopathologically confirmed IGM patients. Patients were divided into two groups: Group 1 who delayed conventional treatment for ≥6 months because they initially chose hirudotherapy, and Group 2 who received standardized stepwise management (steroids, aspiration, or surgery). Clinical outcomes included complete remission, overall recurrence/persistence, clinically significant (extensive/severe) recurrence, fistulizing/complicated recurrence, and the need for surgical intervention.</p><p><strong>Results: </strong>The study included 298 patients, with 41 (13.8%) in Group 1 and 257 (86.2%) in Group 2. Median delay to presentation was significantly longer in Group 1 (15 <i>vs</i>. 1.5 months; <i>p</i><0.001). Complete remission was achieved in only 4.9% (2/41) of Group 1 compared to 59.1% (152/257) in Group 2 (<i>p</i><0.001). Overall recurrence/persistence rates were 95.1% in Group 1 versus 21.8% in Group 2 (<i>p</i><0.001). Among patients who experienced recurrence or persistence, clinically significant (extensive or severe) recurrence occurred in 89.7% (35/39) of Group 1 compared with 42.9% (24/56) of Group 2 (<i>p</i><0.001), while fistulizing/complicated recurrence was significantly higher in Group 1 (26.8% vs. 5.4%; <i>p</i><0.001). In multivariable analysis, hirudotherapy use [odds ratio (OR): 6.7; <i>p</i><0.001] and fistula presence (OR: 9.3; <i>p</i><0.001) were independent predictors of surgical intervention.</p><p><strong>Conclusion: </strong>Initial exclusive reliance on hirudotherapy was associated with markedly lower remission rates, substantially higher rates of clinically significant recurrence, longer delays before medical evaluation, and increased surgical needs despite comparable baseline severity. These findings suggest that hirudotherapy alone does not appear to modify the immune-mediated course of IGM and may result in a higher proportion of refractory cases presenting to hospital settings, as milder cases in the community may resolve spontaneously without seeking care. Early adherence to standardized stepwise care may therefore be important to prevent progression to severe recurrence and reduce the need for surgery. However, further prospective studies are required to confirm these findings.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"417-425"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic and Robotic Minimally Invasive Breast Surgery (MIBS) for Benign Breast Lesions: Our Experience of 80 Cases and Descriptive Comparison.","authors":"Rakesh S Ramesh, Nikhil Dehankar, Guruvasanth Saravanan, Medha Sugara, Vijaya Lakshmi VV, Sujeeth Aroumougame, Neelesh Kanderi","doi":"10.4274/ejbh.galenos.2026.2026-4-3","DOIUrl":"10.4274/ejbh.galenos.2026.2026-4-3","url":null,"abstract":"<p><strong>Objective: </strong>Minimally invasive breast surgery (MIBS) via an extramammary approach offers an alternative to conventional open lumpectomy, eliminating breast scarring and improving psychological outcomes in patients with benign breast lesions. While endoscopic MIBS (EMIBS) has been described, data on robotic MIBS (RMIBS) are sparse. We analyzed the clinical and cosmetic outcomes of EMIBS and RMIBS.</p><p><strong>Materials and methods: </strong>Eighty patients undergoing MIBS for benign breast lumps were divided into endoscopic (<i>n</i> = 40) and robotic (<i>n</i> = 40) groups. Primary endpoints included cosmetic outcomes [evaluated via Patient and Observer Scar Assessment Scale (POSAS) and BREAST-Q], total operative and docking times, and complications, which were statistically analysed (IBM SPSS Statistics version 30).</p><p><strong>Results: </strong>Groups were comparable in age (<i>p</i> = 0.325), lesion size (median 2.0 vs. 2.75 cm; <i>p</i> = 0.247), and number of lumps (median 1 in both groups; <i>p</i> = 0.165). Operative time analysis showed that operative time was significantly longer in the robotic group (median 150 vs. 95 minutes; <i>p</i><0.001). Complications were minor, self-resolving, and comparable across both groups (Fisher's exact <i>p</i> = 0.647). Cosmetic outcomes (at 1 month) were comparable between the two groups: median POSAS score 2 and median BREAST-Q score 88 (breast-conserving therapy module, satisfaction with breasts subscale). A subjective reduction in physical strain on the surgeon was noted in the robotic group; no objective ergonomic measurements were performed.</p><p><strong>Conclusion: </strong>We demonstrate the feasibility and safety of both approaches for benign breast lesions, with comparable and favorable cosmetic outcomes, and with the robotic platform offering subjective improvement in ergonomic strain, especially in difficult-to-access medial quadrants. These findings are hypothesis-generating and require validation using instruments such as NASA-TLX or the Borg CR-10 scale in larger studies.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"476-484"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life After Breast Cancer Surgery in Patients Receiving Adjuvant Radiotherapy: A Cross-Sectional Analysis.","authors":"Hüseyin Kerem Tolan, Şükran Öztürk, Selman Aktaş, Hasan Kumru, Mustafa Kaya, Pouya Aras, Candaş Köseoğlu, Bayramcan Günal, Fatih Emre Yiğit, Kemal Tekeşin, Fatih Başak, Fikret Ezberci","doi":"10.4274/ejbh.galenos.2026.2026-6-11","DOIUrl":"10.4274/ejbh.galenos.2026.2026-6-11","url":null,"abstract":"<p><strong>Objective: </strong>As breast cancer survivorship improves, quality of life (QoL) has become a key determinant in treatment decision-making. While breast-conserving approaches are widely adopted, variations in surgical extent persist across clinical settings. This study aimed to compare patient-reported QoL scores between women undergoing breast-conserving surgery and those undergoing modified radical mastectomy in the context of adjuvant radiotherapy.</p><p><strong>Materials and methods: </strong>This single-center, cross-sectional, observational study included 98 women who were treated at a tertiary hospital between January 2021 and January 2024. Of 200 potentially eligible patients contacted, 98 consented and completed the European Organisation for Research and Treatment of Cancer core quality of life questionnaire (QLQ-C30) and the breast cancer-specific module (QLQ-BR23) after radiotherapy. Fifty-eight patients underwent breast-conserving surgery, and 40 underwent modified radical mastectomy. Scores were transformed to a 0-100 scale; functional and global health scales were interpreted conventionally, and symptom summaries were oriented so that higher scores reflected lower symptom burden. Unadjusted group comparisons were performed using the Mann-Whitney U test, and exploratory correlations were assessed using Spearman correlation coefficients.</p><p><strong>Results: </strong>Patients treated with breast-conserving surgery reported higher QLQ-C30 functional scores than those treated with modified radical mastectomy (median 60.00 <i>vs.</i> 46.66; <i>p</i> = 0.005) and higher global health status scores (66.66 <i>vs.</i> 37.50; <i>p</i><0.001). Symptom summary scores also favored breast conservation (67.94 <i>vs.</i> 58.97; <i>p</i> = 0.001). On the QLQ-BR23, the breast-conserving group reported higher functional scores (57.77 <i>vs.</i> 44.44; <i>p</i> = 0.008) and higher symptom summary scores (87.50 <i>vs.</i> 84.38; <i>p</i> = 0.045). These values represent unadjusted between-group differences and should be interpreted in light of the observational design and the unavailability of clinical covariates.</p><p><strong>Conclusion: </strong>In patients receiving adjuvant radiotherapy, less extensive breast surgery was associated with more favorable patient-reported quality of life outcomes. These findings highlight the importance of incorporating survivorship outcomes into shared decision-making in breast cancer care.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"494-500"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of CT-Derived Skeletal Muscle Metrics for Pathologic Complete Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.","authors":"Günay Rona, Ayşe Özdal Sayer, Sedat Yıldırım, Hatice Odabaş, Bedriye Doğan, Şermin Kökten","doi":"10.4274/ejbh.galenos.2026.2026-6-5","DOIUrl":"10.4274/ejbh.galenos.2026.2026-6-5","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the predictive value of computed tomography (CT)-derived body composition parameters for pathological complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC).</p><p><strong>Materials and methods: </strong>Female patients who received NAC between January 2010 and December 2022 were retrospectively evaluated. Skeletal muscle index (SMI) and muscle density [mean Hounsfield unit (HU)] were measured at the L3 vertebral level on pretreatment CT. Clinicopathological variables, including molecular subtype, histological grade, and clinical stage, were recorded. Treatment response was categorized as pCR or non-pCR. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of pCR. Receiver operating characteristic (ROC) analysis was used to assess the predictive performance of SMI and HU.</p><p><strong>Results: </strong>A total of 365 patients (mean age, 50.2±11.79 years) were included, and pCR was achieved in 27.9% of cases. Molecular subtype was the strongest independent predictor of treatment response, with the highest pCR rates observed in HER2-positive tumors and the lowest in luminal tumors. Histological grade was associated with pCR in univariate analysis but lost significance in multivariate analysis. Neither SMI nor HU independently predicted pCR. Additional analyses according to molecular subtype demonstrated no significant associations between SMI, HU, and treatment response in luminal, HER2-positive, or triple-negative breast cancer subgroups. ROC analyses showed poor discriminatory performance of both parameters in the overall cohort and subtype-specific analyses (area under the curve range, 0.477-0.565).</p><p><strong>Conclusion: </strong>Molecular subtype remains the primary predictor of treatment response following NAC. In contrast, CT-derived SMI and muscle density showed no predictive value for pCR in either the overall cohort or molecular subtype-specific analyses, suggesting that tumor biology plays a more dominant role than body composition in determining treatment response.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"485-493"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Sentinel Lymph Node Biopsy for Breast Cancer in North Africa: A Retrospective Analysis of Feasibility, Safety, and Morbidity Reduction in a Real-World Setting\".","authors":"Wissam Benhami","doi":"10.4274/ejbh.galenos.2026.2026-3-10","DOIUrl":"10.4274/ejbh.galenos.2026.2026-3-10","url":null,"abstract":"","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"518-519"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Versatility of Lateral Intercostal Artery Perforator Flaps in Partial Breast Reconstruction: First National Experience of Peru.","authors":"Marcelo Chávez-Díaz, José Felipe Tapia Amaya, Henry Nevin Salas Parejas, Wilfredo Miguel González Ortiz, Carla Carina Cedrón Lenci, Gabriel de la Cruz Ku, María Del Rosario Cueva Pérez","doi":"10.4274/ejbh.galenos.2026.2026-4-14","DOIUrl":"10.4274/ejbh.galenos.2026.2026-4-14","url":null,"abstract":"<p><strong>Objective: </strong>Oncoplastic breast surgery (OBS) allows wide oncologic resections without compromising breast symmetry. In small-breasted patients with minimal ptosis, volume displacement techniques have limited applicability. Lateral intercostal artery perforators (LICAP)-based perforator flaps allow immediate or delayed partial breast reconstruction for lateral and central defects, preserving muscle and minimizing donor-site morbidity. This study aimed to evaluate the safety and outcomes of LICAP-based flaps and to report the first national experience in Peru.</p><p><strong>Materials and methods: </strong>A retrospective observational study was conducted from August 2023 to August 2025 in patients who underwent OBS with perforator-based flap reconstruction, including LICAP, bilobed LICAP, and combined LICAP-lateral thoracic artery perforator (LTAP) flaps.</p><p><strong>Results: </strong>Twenty patients were included. The mean age was 56.8 years (range, 27-81 years), and 65% were postmenopausal. Indications included invasive ductal carcinoma (85%), ductal carcinoma <i>in situ</i> (5%), and phyllodes tumor (10%). Tumor location: upper outer quadrant (65%), central (20%), upper inner quadrant (10%). Clinical stage IIA was the most frequent (55.5%), and tumors measuring 3-4 cm were observed in 45% of cases. Luminal B was the predominant subtype (40%), and 35% of patients received neoadjuvant chemotherapy. Procedures included bilobed LICAP (35%), LICAP+LTAP (30%), and LICAP (25%). The mean operative time was 134 minutes (range, 90-195 minutes), and the mean pathological tumor size was 3.57 cm (range, 0-7 cm). Negative margins were achieved in 95% of patients. Surgical complications (Clavien-Dindo grade I) occurred in 15%. During a median follow-up of 22.5 months (range, 10-24 months), no locoregional recurrences were observed.</p><p><strong>Conclusion: </strong>LICAP-based volume replacement OBS is a versatile, safe, and reproducible technique that may expand the indications for breast-conserving surgery in selected patients and yields encouraging short-term outcomes comparable to those reported in international series.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"455-465"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Surgical Delay After Neoadjuvant Chemotherapy on Survival Outcomes in Breast Cancer: A Systematic Review and Meta-Analysis.","authors":"Gladys Mae V Gallego, Felicidad Claudia R Ordoñez","doi":"10.4274/ejbh.galenos.2026.2026-4-1","DOIUrl":"10.4274/ejbh.galenos.2026.2026-4-1","url":null,"abstract":"<p><p>Timely surgery after neoadjuvant chemotherapy (NAC) is essential in breast cancer management, yet delays remain common, particularly in low- and middle-income countries. Evidence on the impact of these delays is inconsistent. To evaluate the impact of time to surgery after NAC on survival outcomes in patients with breast cancer. This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. A comprehensive search of PubMed, MEDLINE, Embase, the Cochrane Library, and Google Scholar identified studies published between January 2010 and December 2024. Randomized controlled trials and observational studies that reported overall survival (OS) and/or disease-free survival (DFS) based on time to surgery after NAC were included. Study selection and data extraction were performed by two independent reviewers. Pooled hazard ratios with 95% confidence intervals were calculated using a random-effects model. Heterogeneity was assessed using the I2 statistic. Thirteen studies, comprising thousands of patients, were included. Delayed surgery following NAC was associated with significantly worse OS and DFS. Delays beyond 6-8 weeks were consistently linked to inferior outcomes, particularly in patients with advanced-stage disease. Moderate heterogeneity was observed across studies. Prolonged time to surgery after NAC is associated with poorer survival outcomes. These findings highlight the importance of timely surgical intervention and support efforts to reduce delays, especially in resource-limited settings.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"374-385"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Entity in Context: Breast Implant-Associated Anaplastic Large Cell Lymphoma Compared With Common Lymphoma Subtypes.","authors":"Dina Tluli, Omar Tluli, Mahd M Abujbara, Rawan Boudaka, Sheraz Abayazeed Ahmed, Giridhara Rathnaiah Babu, Semir Vranic","doi":"10.4274/ejbh.galenos.2026.2026-6-1","DOIUrl":"10.4274/ejbh.galenos.2026.2026-6-1","url":null,"abstract":"<p><strong>Objective: </strong>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare CD30-positive, anaplastic lymphoma kinase (ALK)-negative peripheral T-cell lymphoma now recognized as a distinct entity in the 5^th edition World Health Organization Classification of haematolymphoid tumors. Its clinicopathologic profile, treatment patterns, and outcomes, relative to those of other primary breast lymphomas, have not been characterized in large population-based comparative studies.</p><p><strong>Materials and methods: </strong>Using the Surveillance, Epidemiology and End Results (SEER) database (2017-2022), we identified patients with primary breast lymphoma based on ICD-O-3 site (C50.0-C50.9) and morphology codes for BIA-ALCL (9715/3), diffuse large B-cell lymphoma (DLBCL, 9680/3), extranodal marginal zone [mucosa-associated lymphoid tissue (MALT)] lymphoma (9699/3), and Burkitt lymphoma (BL, 9687/3). Baseline characteristics, treatment, overall survival (OS), and cancer-specific survival (CSS) were compared between BIA-ALCL and other mammary lymphomas.</p><p><strong>Results: </strong>Two hundred fifty-two patients with BIA-ALCL were identified and compared with 185,019 patients with other mammary lymphomas. Patients with BIA-ALCL were younger than those with DLBCL and MALT, but older than those with BL (mean age 62.8 years, <i>p</i><0.001). BIA-ALCL demonstrated higher rates of surgical management and lower rates of radiotherapy compared with DLBCL and MALT. Chemotherapy utilization was intermediate among lymphoma subtypes. In unadjusted analyses, DLBCL was associated with worse OS [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.03-2.08] and CSS (HR 1.84, 95% CI 1.21-2.79) relative to BIA-ALCL; BL was associated with worse CSS (HR 2.08, 95% CI 1.37-3.16); MALT lymphoma showed better CSS (HR 0.54, 95% CI 0.35-0.81). Multivariable analysis yielded HRs that were not statistically distinguishable from those for BIA-ALCL, but estimates were imprecise (adjusted OS for DLBCL: HR 1.53, 95% CI 0.21-10.90; for BL: HR 2.66, 95% CI 0.37-19.20); these wide CIs reflect sparse events within the BIA-ALCL cohort and preclude conclusions about survival equivalence.</p><p><strong>Conclusion: </strong>In this SEER-based analysis, breast-localized ALK-negative ALCL showed a distinct demographic and treatment profile characterized by surgical management, with favorable crude survival compared with that of DLBCL and BL. Early recognition and complete surgical excision remain central to the management of localized BIA-ALCL.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"466-475"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum.","authors":"","doi":"10.4274/ejbh.galenos.2026.e001","DOIUrl":"10.4274/ejbh.galenos.2026.e001","url":null,"abstract":"","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"525"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Merkel Cell Carcinoma of the Breast - A Report of an Extremely Rare Case.","authors":"Anna Sachoulidou, Andreas Simeou, Themis Anastasia Tataridou, Aichan Bozoglou, Anastasios Boutis, Ioannis Galanis","doi":"10.4274/ejbh.galenos.2026.2025-4-7","DOIUrl":"10.4274/ejbh.galenos.2026.2025-4-7","url":null,"abstract":"<p><p>Neuroendocrine carcinoma of the breast is a very rare malignancy, and when it presents with characteristics similar to Merkel cell carcinoma (MCC), it is even more uncommon. This report discusses a case of small cell carcinoma exhibiting Merkel cell-like features in an 80-year-old woman who had a history of rheumatoid arthritis under treatment with immunosuppressive drugs. Microscopic analysis showed tissue fragments with areas of necrosis, as well as focal regions containing neoplastic cells. These cells were small to medium in size, with poorly defined borders, scant cytoplasm, and hyperchromatic, atypical nuclei. Immunohistochemical staining revealed perinuclear (dot-like) positivity for cytokeratin 18/8 and strong positivity for cytokeratin 20 and cluster of differentiation 56. The cell proliferation marker Ki-67 was positive in over 80% of the cells. What is extremely rare in this case is the presentation of MCC of the breast as a retro areolar lesion, located behind the areola and associated with nipple discharge, without evidence of a primary cutaneous lesion.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"505-510"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}